Please login to the form below

Not currently logged in
Email:
Password:

Galena starts registration for breast cancer vaccine trial

NeuVax aims to prevent recurrence in women ineligible for treatment with Roche’s Herceptin

Galena Biopharma has started a phase III trial of its breast cancer vaccine NeuVax with the aim of preventing recurrence in women who are not eligible for treatment with Roche's Herceptin.

The 700-patient study will enrol women with low or intermediate expression of the HER2 breast cancer biomarker, a group which accounts for around half of all breast cancer patients.

“These patients are successfully rendered disease-free following treatment with current standards of care, and are then sent home to watch and wait with the hope their cancer never returns,” said Beth Mittendorf of MD Anderson Cancer Center in the US, the principal investigator in the new trial.

Prior results from a phase I/II trial have suggested that NeuVax can “maintain disease-free survival in these patients who have no other [adjuvant treatment] options”, she added.

If successful, the new study – called PRESENT – could be sufficient in its own right to support marketing approval for NeuVax, according to Galena.

That could mean impressive returns for investors in the Oregon-based biotech, which currently has a market capitalisation of just $30m, according to analysts at Zacks Investment Research.

NeuVax could “easily” top $1bn in sales if it is approved for use in the 20,000 or so eligible breast cancer patients who are diagnosed each year in the US, the analysts added.

The company has also forged an alliance with Roche subsidiary Genentech to conduct a phase II study looking at the combination of NeuVax with Herceptin (trastuzumab) in 300 patients intermediate HER2 status patients who are currently not eligible for Herceptin treatment.

NeuVax consists of the E-75 peptide from the HER2/neu protein as an antigen, delivered alongside an immune stimulator (granulocyte macrophage colony-stimulating factor/GM-CSF). Galena acquired rights to the vaccine from the US military in July 2011.

24th January 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Mednet Group

Communique Small consultancy of the year 2020. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC...

Latest intelligence

Numbers, navigation, and narratives: digital storytelling in medical communications
Science and storytelling aren’t often seen as compatible. One is based on cold, hard facts, while the other is synonymous with improvisation and theater. However, when done well, storytelling can...
Is this common data mistake killing your digital patient recruitment?
Without realising, you could be falling into the trap of using social data — insights into recent, relevant trends and topics — to inspire your content. Hold up. That sounds...
Stick or Twist? Healthcare brands in a (post) COVID-19 world
...